Nurse Practitioner Program year 2025 Source: CMS Open Payments, 2026 publication

Tina Galey

Nurse Practitioner Astoria, OR Nurse Practitioner

NPI 1437229366 CMS profile 10550667

2158 Exchange St, Suite 304, Astoria, OR 97103

Open in the dashboard

General payments

$1,197

52 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tina Galey of Astoria, OR is reported in the CMS Open Payments database as having received $1,197 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $1,197 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tina Galey
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Tina Galey were reported at $1,197. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Tina Galey Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $1,197 $174 $55–$557 $169

Breakdown

Who paid General payments · program year 2025
  1. AstraZeneca Pharmaceuticals LP $176 8 payments
  2. Astellas Pharma US Inc $125 2 payments
  3. ITI, Inc. $112 5 payments
  4. AbbVie, Inc. $107 4 payments
  5. Exact Sciences Corporation $84 4 payments
  6. Otsuka America Pharmaceutical, Inc. $76 4 payments
  7. Phathom Pharmaceuticals, Inc. $58 4 payments
  8. Sumitomo Pharma America, Inc. $55 2 payments
  9. Novo Nordisk Inc $44 2 payments
  10. Organon LLC $39 2 payments
  11. Other $320 15 payments

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $1,097 51 payments
  2. Education $100 1 payment
Products named General payments · program year 2025
  1. AIRSUPRA $118 5 payments
  2. CAPLYTA $112 5 payments
  3. QULIPTA $107 4 payments
  4. The Cologuard Plus Collection Kit $84 4 payments
  5. UBRELVY $74 3 payments
  6. REXULTI $60 3 payments
  7. VOQUEZNA $58 4 payments
  8. GEMTESA $55 2 payments
  9. Wegovy $44 2 payments
  10. NEXPLANON $39 2 payments
  11. Other $592 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 133 drugs

Part D claims

7,221

Median for Nurse Practitioner: 389

Drug cost

$405,897

Median for Nurse Practitioner: $21,885

Branded share of claims

21.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 123 $89,741
Trulicity Dulaglutide Brand 51 $66,475
Jardiance Empagliflozin Brand 59 $38,802
Ozempic Semaglutide Brand 25 $24,974
Xarelto Rivaroxaban Brand 22 $14,915
Oxycontin Oxycodone Hcl Brand 27 $14,695
Breo Ellipta Fluticasone/Vilanterol Brand 30 $11,970
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 108 $6,820
Albuterol Sulfate Hfa Albuterol Sulfate Brand 150 $6,420
Advair Hfa Fluticasone Propion/Salmeterol Brand 17 $6,345

The 10 drugs with the highest cost, of 133 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$596

Medicare's payments for the services billed

Medicare patients

45

Average age 69

Services billed

65

23 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 71%
High blood pressure 69%
Arthritis 44%
COPD 33%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record